Abstract
Objective To evaluate the frequency of snoozing, schmoozing, perusing, and boozing among attendees at an international conference.
Design Survey and field study
Setting The 9th International Congress on Peer Review and Scientific Publication in Chicago, Illinois (the conference).
Participants 53 attendees (perhaps just enough to be scientific).
Main outcome measures Self-reported conference behavior including frequency of falling asleep (snoozing), interacting with other attendees (schmoozing), and multi-tasking (perusing) during presentations, as well as drinking (boozing) at the conference.
Results 53 attendees completed the survey, which represents a 100% response rate among the attendees who decided to complete the survey. Most of the respondents reported that they preferred in-person conferences before (47/53, 89%) and since (43/53, 81%) the COVID-19 pandemic. 49 (49/53, 92%) reported that multi-day, in-person conferences are still a good use of time. Although 49 (49/53, 92%) reported learning something new (new views), nearly half (24/49, 49%) stated that they could have learned this information from a book or journal article, as opposed to traveling to a conference. Two respondents (2/51, 4%) admitted to snoozing and 43 (84%) to perusing (e.g., emailing, working, and using Twitter) during presentations on the first day of the conference (we suspect that all 5 respondents who claimed that their sleep schedule was “none of our business” also snoozed regularly). The rate of boozing (up to 3 alcoholic beverages) on the first night of the conference was alarming (39/52, 75%), with an additional 10% unable to recall the total number of drinks consumed.
Conclusions Formal, presentation-based conferences may no longer be needed, as attendees appear to be overly preoccupied with snoozing, schmoozing, perusing, and boozing.
What is already known on this topic
- Scientific conferences have functioned as both professional and social events, allowing attendees to learn about the newest research findings while they schmooze, and sometimes booze, with their colleagues.
- Since the COVID-19 pandemic, the research community has grown increasingly accustomed to the benefits of attending conferences from behind their computers.
- Little is known about the behaviors and preferences of attendees following the COVID-19 conference hiatus.
What this study adds
- Almost all respondents reported that multi-day, in-person conferences were still a good use of time and that they had learned something new (even though over half admitted that they could have learned this information from a book or journal article, as opposed to traveling to a conference)
- Conference attendees rarely snoozed but frequently perused (email, work, and Twitter) during presentations; over three-quarters boozed on the first night of the conference.
- Formal, presentation-based conferences may no longer be needed, as attendees appear to be overly preoccupied with snoozing, schmoozing, perusing, and boozing.
Competing Interest Statement
Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International; in addition, Dr. Ross is an expert witness at the request of Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. and is the U.S. Outreach and an Associate Editor at The BMJ. Dr. Wallach currently received research support from the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under award K01AA028258, the Food and Drug Administration, Arnold Ventures, and through Yale University from Johnson & Johnson. He served as a consultant for Hagens Berman Sohol Shapiro LLP and Dugan Law Firm APLC.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Yale University waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon request to the authors.
